Otsuka (OTSKY) Expected to Post Quarterly Earnings on Thursday

Otsuka (OTCMKTS:OTSKY) will likely be posting its resultson Thursday, July 30th. Analysts expect the company to post earnings of $0.4870 per share and revenue of $3.9577 billion for the quarter. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS.

Otsuka (OTCMKTS:OTSKY) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.16. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. The company had revenue of $3.96 billion for the quarter, compared to analysts’ expectations of $3.78 billion. On average, analysts expect Otsuka to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Otsuka Stock Down 1.3%

OTCMKTS OTSKY opened at $33.64 on Thursday. Otsuka has a 12 month low of $22.43 and a 12 month high of $37.52. The company has a market capitalization of $36.14 billion and a P/E ratio of 14.20. The company’s 50 day simple moving average is $34.35 and its 200 day simple moving average is $33.27. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.17 and a quick ratio of 1.67.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Otsuka currently has an average rating of “Hold”.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.